Fig. 8

AGAP2-AS1 expression is associated with chemoresponse to trastuzumab therapy in patients with breast cancer. a The expressions of AGAP2-AS1 and MyD88 in 42 paired breast cancer tissues. b The statistically significant association between AGAP2-AS1 and MyD88 expression in breast cancer specimens. c AGAP2-AS1 expression was determined via RT-qPCR for the trastuzumab-resistant and sensitive patients. d ROC curve was established to show the ability of AGAP2-AS1 in differentiating responding patients from non-responding patients. e The proportion of patients that showed resistance to trastuzumab therapy was significantly higher in high AGAP2-AS1 expressing groups than in low expression group. ***p < 0.001